Cyclarity (formerly Underdog Pharmaceuticals) published an article on their technology to use Cyclodextrin molecules to encapsulate "toxic biomolecules" including 7-ketocholesterol which they believe is linked to atherosclerosis and macular degeneration. I think this might be the approach they are using with their candidate drug linked above.
https://www.sciencedirect.com/science/article/pii/S037851732...
I get the impression that Cyclodextrins are far from perfect, but at least there is some hope for non-invasive treatments in future.
Here are some of the links I've read recently, which sound promising to me (a non-expert in this field).
Microarray patches to deal with bio-availability of Cyclodextrin: https://www.sciencedirect.com/science/article/pii/S014486172...
Cholrem company has a commercial product Cavadex, which they claim can reverse arterial plaque: https://www.cholrem.com/
Cyclarity Therapeutics have a Cyclodextrin candidate drug they are hoping to start trials on next year: https://cyclaritytx.com/our-science/
Cyclarity (formerly Underdog Pharmaceuticals) published an article on their technology to use Cyclodextrin molecules to encapsulate "toxic biomolecules" including 7-ketocholesterol which they believe is linked to atherosclerosis and macular degeneration. I think this might be the approach they are using with their candidate drug linked above. https://www.sciencedirect.com/science/article/pii/S037851732...
I get the impression that Cyclodextrins are far from perfect, but at least there is some hope for non-invasive treatments in future.